{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:50:09Z","timestamp":1747284609557,"version":"3.40.3"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Jieyang Science and Technology Bureau Medical Science and Technology Innovation Project","award":["ylsm090"],"award-info":[{"award-number":["ylsm090"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,7]]},"abstract":"<jats:p>Multiple myeloma (MM) is an incurable hematologic malignancy, with chemotherapy being the primary treatment. However, the development of drug resistance remains a major challenge. This study aimed to identify therapeutic targets associated with drug resistance in MM and assess their prognostic significance. Gene expression data from GSE82307, GSE146649, and GSE136725 were analyzed to identify differentially expressed genes (DEGs) using the \u201climma\u201d and \u201cRobustRankAggreg\u201d R packages. Functional enrichment analysis and protein\u2013protein interaction (PPI) network analysis were performed, with key network modules identified using Cytoscape. The expression and prognostic relevance of DEGs were validated using MM patient samples from the GSE136725 and MMRF CoMMpass databases. A total of 4623 DEGs were identified, and robust rank aggregation analysis revealed the top 20 upregulated genes. Among them, AURKA, DLGAP5, BUB1B, and KIF20A were highly expressed in drug-resistant patients and were associated with poor prognosis. The findings suggest that AURKA, DLGAP5, BUB1B, and KIF20A are potential biomarkers linked to drug resistance and recurrence in MM. Further studies are required to elucidate the underlying molecular mechanisms and explore their potential as therapeutic targets.<\/jats:p>","DOI":"10.1097\/md.0000000000041707","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:30:08Z","timestamp":1743208208000},"page":"e41707","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive bioinformatics analysis reveals key hub genes linked to prognosis in multiple myeloma with drug resistance"],"prefix":"10.1097","volume":"104","author":[{"given":"Xi-tian","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, Jieyang People\u2019s Hospital, Jieyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-peng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Brain Centre, Jiexi County second People\u2019s Hospital, Jieyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-qing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jieyang People\u2019s Hospital, Jieyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Jieyang People\u2019s Hospital, Jieyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le-yang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiexi County second People\u2019s Hospital, Jieyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Rongcheng District Central Hospital, Jieyang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1203-3276","authenticated-orcid":false,"given":"Gui-yang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Rongcheng District Central Hospital, Jieyang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250328","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma.","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"R2-20250328","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R3-20250328","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance.","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R4-20250328","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma.","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"R5-20250328","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.","volume":"13","author":"Vo","year":"2022","journal-title":"Nat Commun"},{"key":"R6-20250328","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41416-020-01191-y","article-title":"Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.","volume":"124","author":"Ge","year":"2021","journal-title":"Br J Cancer"},{"key":"R7-20250328","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"R8-20250328","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-020-01005-x","article-title":"RNA sequencing: new technologies and applications in cancer research.","volume":"13","author":"Hong","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R9-20250328","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm.","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"R10-20250328","doi-asserted-by":"crossref","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets--update.","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"R11-20250328","doi-asserted-by":"crossref","first-page":"152375","DOI":"10.1016\/j.prp.2019.03.004","article-title":"The expression of miR-375 in prostate cancer: a study based on GEO, TCGA data and bioinformatics analysis.","volume":"215","author":"He","year":"2019","journal-title":"Pathol Res Pract"},{"key":"R12-20250328","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1186\/s12885-022-09736-5","article-title":"Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer.","volume":"22","author":"Ucaryilmaz Metin","year":"2022","journal-title":"BMC Cancer"},{"key":"R13-20250328","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/bioinformatics\/btr709","article-title":"Robust rank aggregation for gene list integration and meta-analysis.","volume":"28","author":"Kolde","year":"2012","journal-title":"Bioinformatics"},{"key":"R14-20250328","doi-asserted-by":"crossref","first-page":"726747","DOI":"10.3389\/fimmu.2021.726747","article-title":"Identifying immune cell infiltration and effective diagnostic biomarkers in rheumatoid arthritis by bioinformatics analysis.","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"R15-20250328","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"R16-20250328","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.3390\/ijms21113854","article-title":"Imprinting of mesenchymal stromal cell transcriptome persists even after treatment in patients with multiple myeloma.","volume":"21","author":"Lemaitre","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R17-20250328","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters.","volume":"16","author":"Yu","year":"2012","journal-title":"Omics"},{"key":"R18-20250328","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/nar\/gkg034","article-title":"STRING: a database of predicted functional associations between proteins.","volume":"31","author":"von Mering","year":"2003","journal-title":"Nucleic Acids Res"},{"issue":"Suppl 4","key":"R19-20250328","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","article-title":"cytoHubba: identifying hub objects and sub-networks from complex interactome.","volume":"8","author":"Chin","year":"2014","journal-title":"BMC Syst Biol"},{"key":"R20-20250328","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.16744","article-title":"Development of an RNA sequencing-based prognostic gene signature in multiple myeloma.","volume":"192","author":"Zamani-Ahmadmahmudi","year":"2021","journal-title":"Br J Haematol"},{"key":"R21-20250328","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma.","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R22-20250328","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/ijms23031649","article-title":"Multiple myeloma: challenges encountered and future options for better treatment.","volume":"23","author":"Das","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R23-20250328","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.cellsig.2013.01.020","article-title":"Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe.","volume":"25","author":"Cives","year":"2013","journal-title":"Cell Signal"},{"key":"R24-20250328","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13046-020-01597-9","article-title":"A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.","volume":"39","author":"Hu","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"R25-20250328","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1002\/cncr.30174","article-title":"A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent\/refractory multiple myeloma.","volume":"122","author":"Chari","year":"2016","journal-title":"Cancer"},{"key":"R26-20250328","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","article-title":"The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma.","volume":"115","author":"Spagnuolo","year":"2010","journal-title":"Blood"},{"key":"R27-20250328","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/1535-7163.MCT-09-0645","article-title":"The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance.","volume":"9","author":"Meinel","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"R28-20250328","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2009-10-251660","article-title":"GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.","volume":"115","author":"Streetly","year":"2010","journal-title":"Blood"},{"key":"R29-20250328","doi-asserted-by":"crossref","first-page":"11100","DOI":"10.18632\/aging.103326","article-title":"ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L.","volume":"12","author":"Liu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"R30-20250328","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood-2010-01-264424","article-title":"APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status.","volume":"117","author":"Quinn","year":"2011","journal-title":"Blood"},{"key":"R31-20250328","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/CBM-203170","article-title":"Upregulated mitosis-associated genes CENPE, CENPF, and DLGAP5 predict poor prognosis and chemotherapy resistance of Acute Myeloid Leukemia.","volume":"35","author":"Shi","year":"2022","journal-title":"Cancer Biomark"},{"key":"R32-20250328","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2016.325","article-title":"Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma.","volume":"31","author":"Qin","year":"2017","journal-title":"Leukemia"},{"key":"R33-20250328","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41392-021-00746-6","article-title":"BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability.","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R34-20250328","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12032-015-0542-x","article-title":"BUB1B promotes multiple myeloma cell proliferation through CDC20\/CCNB axis.","volume":"32","author":"Yang","year":"2015","journal-title":"Med Oncol"},{"key":"R35-20250328","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.2147\/OTT.S115974","article-title":"Positive expression of KIF20A indicates poor prognosis of glioma patients.","volume":"9","author":"Duan","year":"2016","journal-title":"Onco Targets Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:43:00Z","timestamp":1743363780000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041707","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}